Last reviewed 2026-04-19 · How we verify

Bacterial septicemia

Approved treatments

• MEZLOCILLIN
• Ramycin
  Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins.
• Garamycin · Merck & Co.
• Eryped · Arbor Pharms Llc
• Metacillin · Bristol-Myers Squibb
• Cefaprin · Bristol-Myers Squibb
• Ancef In Sodium Chloride 0.9% In Plastic Container · GSK
• Ancef In Sodium Chloride 0.9% In Plastic Container · GSK
  Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis.
• Cleocin T · Pfizer
  Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
• Tobi · Novartis
• Vancocin · ANI Pharmaceuticals
• Claforan · Sterimax
• Unasyn · Bristol-Myers Squibb
• Cleocin · Generic (originally Upjohn/Pfizer)
  Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage.
• Metro I.V. In Plastic Container · Baxter
• Pipracil
  Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.
• Vantobra · Pfizer
• Gentamicin · Merck & Co.
• Cefadole
  Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Nebcin · University Hospital, Lille
• Ceftriaxon · Centre Hospitalier Universitaire Vaudois
• Cortisporin · Pfizer
• Primaxin · Merck Sharp & Dohme B.V.
  Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Arikayce Kit · Bristol-Myers Squibb
  Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
• Fortaz · Pai Holdings Pharm
  Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.
• Mefoxin In Sodium Chloride 0.9% In Plastic Container
• Monocid
• Cefotan
• Primaxin · Merck & Co.
  Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body.
• AZLOCILLIN · Bayer Pharmaceuticals Corp
• Cephalotin · Eli Lilly
• TICARCILLIN
• Ticarcillin
• Zinacef · GSK
  Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Kanacin · Bristol-Myers Squibb
• Augmentin 250 · Dr Reddys Labs Inc
• Fortaz · Pai Holdings Pharm
  Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.
• Epocelin
• Rocephin · Generic (originally Roche)
• Cephazolin · HaEmek Medical Center, Israel
• Cefazoline · Nantes University Hospital
• Ceftazidim · Tel-Aviv Sourasky Medical Center
• Metronidazol · University of Oslo

Clinical guidelines

• FDA label — 1L
  Ceftazidime is indicated for the treatment of bacterial septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).
• FDA label — 1L
  Tobramycin injection is indicated for the treatment of septicemia in pediatric patients and adults caused by P. aeruginosa, E. coli, and Klebsiella spp.
• FDA label — 1L
  Tobramycin injection is indicated for the treatment of lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains).
• FDA label — 1L
  Tobramycin injection is indicated for the treatment of serious central-nervous-system infections (meningitis) caused by susceptible organisms.
• FDA label — 1L
  Tobramycin injection is indicated for the treatment of intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp.
• FDA label — 1L
  Tobramycin injection is indicated for the treatment of skin, bone, and skin structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, and S. aureus.
• FDA label — 2L
  Tobramycin injection is indicated for the treatment of complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia spp, and Citrobacter spp. Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxic

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Bacterial septicemia patent landscape — cliff calendar, originator estates, attackable patents
• Bacterial septicemia treatment landscape brief
• Bacterial septicemia treatment updates RSS

Frequently asked questions about Bacterial septicemia

Related

• Treatment landscape: Bacterial septicemia patent cliff · Bacterial septicemia CI report
• Treatment: MEZLOCILLIN
• Treatment: Ramycin
• Treatment: Garamycin · Merck & Co.
• Treatment: Eryped · Arbor Pharms Llc
• Treatment: Metacillin · Bristol-Myers Squibb
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing